We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Besides the ability to achieve complex structures and release profiles of drugs, this novel platform has the ability to personalize prescription medicines, allowing for doctors to tailor accurately the exposure and dosage levels for individual patients.
Amerigen Pharmaceuticals Limited ("Amerigen") and Dipharma S.A. ("Dipharma") today announced that Amerigen's Abbreviated New Drug Application ("ANDA") for Miglustat 100 mg capsules has received final approval from the FDA